Avesthagen Limited announced the start of Phase III human clinical trials for it's recently launched Avestaä brand of botanical bioActives. Avesthagen Limited and Manipal AcuNova Limited, Bangalore have a strategic agreement for conducting the Phase III human clinical studies for diabetes management for Avesthagen's branded bioActives TeestarTM, AspandTM and CincataTM. These products have been developed by the bionutrition division of Avesthagen Limited from different medicinal plants selected from its proprietary database - ADePtTM, and validated using MetaGridTM, its patented comprehensive constituent profiling technology.
TeestarTM acts by intervening with carbohydrate metabolism. The efficacy of TeestarTM was evaluated in pre-clinical studies wherein it showed significant reduction of blood glucose levels. AspandTM acts by inhibiting Dipeptidyl peptidase IV and by sensitising insulin. AspandTM was tested on different cell lines in-house in different assays, where AspandTM treated group showed inhibition of Dipeptidyl peptidase IV and better glucose homeostasis as compared to the control.
CincataTM acts by inhibiting a-glucosidase and by acting synergistically with insulin, thereby increasing its potency. CincataTM was tested on different cell lines in-house in different assays, where CincataTM treated group showed inhibition of a-glucosidase, and better glucose homeostasis as compared to the control. During pre-clinical studies all three bioActives recorded a significant decrease in blood sugar levels in diabetic animal models and also recorded a significant reduction in the level of glycated haemoglobin HbA1c in comparison to the controls.
BG Content 
